Cargando...
The paradigm shift to an “open” model in drug development
The rising cost of healthcare, the rising cost for drug development, the patent cliff for Big pharma, shorter patent protection, decrease reimbursement, and the recession have made it more difficult for the pharmaceutical and biotechnology industry to develop drugs. Due to the unsustainable amount o...
Gardado en:
| Publicado en: | Appl Transl Genom |
|---|---|
| Autor Principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Elsevier
2014
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4888825/ https://ncbi.nlm.nih.gov/pubmed/27294020 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.atg.2014.09.001 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|